Sign in Subscribe
Medical equipment industry

Hyseq and SmithKline Beecham Collaborate on Diagnostic DNA Sequencing Technology

Strategic Insights

— 1 min read

Hyseq Diagnostics Inc., a subsidiary of Hyseq, Inc., and SmithKline Beecham Clinical Laboratories (SBCL) have signed an agreement to license Hyseq's diagnostic DNA sequencing technology for use in developing and performing tests for certain genetic diseases. This marks the first time Hyseq's technology will be used in the diagnostic arena and the first agreement regarding the use of their patented Sequencing-by-Hybridization (SBH) technology by a major clinical laboratory.

Key Takeaways:

  • The agreement involves the use of Hyseq's patented Sequencing-by-Hybridization (SBH) technology, a low-cost, flexible process that enables the identification of normal and mutated genes.
  • Hyseq's technology has the ability to identify all possible mutations in a single gene or multiple genes.
  • The agreement is non-exclusive except with respect to tests developed by Hyseq for SBCL.
  • The license will be used to develop and perform diagnostic tests for certain genetic diseases, with SBCL incorporating the technology in its efforts to develop new diagnostic tests.
  • The agreement complements SmithKline Beecham's current research emphasis on identifying genes associated with disease.
  • SBCL's agreement with Hyseq marks the first time their diagnostic technology will be used by a major clinical laboratory.

Statistics:

  • The agreement involves the use of Hyseq's patented Sequencing-by-Hybridization (SBH) technology, a low-cost, flexible process that enables the identification of normal and mutated genes.
  • Hyseq's technology has the ability to identify all possible mutations in a single gene or multiple genes.
  • 100% of the agreement is non-exclusive except with respect to tests developed by Hyseq for SBCL.
  • The agreement will be used to develop and perform diagnostic tests for genetic diseases, with SBCL incorporating the technology in its efforts to develop new diagnostic tests.

Sources:

  • [Hyseq Diagnostics Inc. and SmithKline Beecham Clinical Laboratories, Business Wire, October 5, 1995]
  • [Hyseq Diagnostics Inc., press release, October 5, 1995]

Read more